Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

NCT01969318 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Placebo /Metformin
DRUG: SP2086(50 mg q.d.)/Metformin
DRUG: SP2086 (100 mg q.d.)/Metformin

Sponsor

Jiangsu HengRui Medicine Co., Ltd.